Schuurman is a thought leader and an active Board Member of The Antibody Society, an international, non-profit trade association representing individuals and organizations involved in antibody-related research and development. Dr. Schuurman was one of the first scientists joining Genmab's R&D team, and for over 22 years worked to develop innovative antibody therapeutics at Genmab, with her most recent position being Genmab's Senior Vice President heading Antibody Research and Technologies. Dr. Schuurman is a co-inventor of the DuoBody®, HexaBody® and HexElect® technologies that enable the generation of bispecific and effector-function enhanced antibodies. These technologies are being applied to antibody therapeutics discovery programs at leading pharmaceutical and biotechnology companies worldwide and have resulted in FDA approved therapies such as RYBREVANT® (amivantamab-vmjw) and EPKINLY™ (epcoritamab-bysp). Dr. Schuurman received her Ph.D. in Immunology from the University of Amsterdam.